Rene A. Braeckman

2.4k total citations
63 papers, 1.9k citations indexed

About

Rene A. Braeckman is a scholar working on Nutrition and Dietetics, Surgery and Pharmacology. According to data from OpenAlex, Rene A. Braeckman has authored 63 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Nutrition and Dietetics, 16 papers in Surgery and 14 papers in Pharmacology. Recurrent topics in Rene A. Braeckman's work include Fatty Acid Research and Health (18 papers), Lipoproteins and Cardiovascular Health (13 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (11 papers). Rene A. Braeckman is often cited by papers focused on Fatty Acid Research and Health (18 papers), Lipoproteins and Cardiovascular Health (13 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (11 papers). Rene A. Braeckman collaborates with scholars based in United States, United Kingdom and Netherlands. Rene A. Braeckman's co-authors include Paresh N. Soni, Christie M. Ballantyne, Harold Bays, John J.P. Kastelein, William G. Stirtan, Jonathan L. Isaacsohn, Evan A. Stein, G. Richard Granneman, Ralph T. Doyle and Rebecca A. Juliano and has published in prestigious journals such as Circulation, Antimicrobial Agents and Chemotherapy and Journal of the American Academy of Child & Adolescent Psychiatry.

In The Last Decade

Rene A. Braeckman

63 papers receiving 1.8k citations

Peers

Countries citing papers authored by Rene A. Braeckman

Since Specialization

Citations

This map shows the geographic impact of Rene A. Braeckman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rene A. Braeckman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rene A. Braeckman more than expected).

Fields of papers citing papers by Rene A. Braeckman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rene A. Braeckman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rene A. Braeckman. The network helps show where Rene A. Braeckman may publish in the future.

Co-authorship network of co-authors of Rene A. Braeckman

This figure shows the co-authorship network connecting the top 25 collaborators of Rene A. Braeckman. A scholar is included among the top collaborators of Rene A. Braeckman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rene A. Braeckman. Rene A. Braeckman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Serdexmethylphenidate/dexmethylphenidate for children with attention-deficit/hyperactivity disorder: dose optimization from a laboratory classroom study 2024 ·Frontiers in Psychiatry ·Andrew J. Cutler, Scott H. Kollins, Matthew Brams, (unknown), Charles Oh, Rene A. Braeckman, Ann Childress	1
2	Dose Proportionality and Steady-State Pharmacokinetics of Serdexmethylphenidate/Dexmethylphenidate, a Novel Prodrug Combination to Treat Attention-Deficit/Hyperactivity Disorder 2022 ·Journal of Child and Adolescent Psychopharmacology ·Rene A. Braeckman, (unknown), (unknown), Andrew C. Barrett, Adam J. Smith, Charles Oh	15
3	Comparison of Steady-State Pharmacokinetics of Donepezil Transdermal Delivery System with Oral Donepezil 2022 ·Journal of Alzheimer s Disease ·Pierre N. Tariot, Rene A. Braeckman, Charles Oh	12
4	A Randomized, Controlled Laboratory Classroom Study of Serdexmethylphenidate and d-Methylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder 2021 ·Journal of Child and Adolescent Psychopharmacology ·Scott H. Kollins, Rene A. Braeckman, (unknown), Andrew C. Barrett, (unknown), Charles Oh, (unknown), Andrew J. Cutler, Matthew Brams	27
5	Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effects Upon High-Sensitivity C-Reactive Protein and Lipid Parameters in Patients With Metabolic Syndrome 2015 ·Metabolic Syndrome and Related Disorders ·Harold Bays, Christie M. Ballantyne, Rene A. Braeckman, William G. Stirtan, Ralph T. Doyle, Sephy Philip, Paresh N. Soni, Rebecca A. Juliano	19
6	Effect of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Omeprazole Plasma Pharmacokinetics in Healthy Adults 2014 ·Drugs in R&D ·Rene A. Braeckman, William G. Stirtan, Paresh N. Soni	10
7	Effect of Concomitant Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on the Pharmacokinetics of Atorvastatin 2014 ·Clinical Drug Investigation ·Rene A. Braeckman, William G. Stirtan, Paresh N. Soni	7
8	Icosapent ethyl, a pure EPA omega-3 fatty acid: Effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study) 2013 ·Prostaglandins Leukotrienes and Essential Fatty Acids ·Rene A. Braeckman, Mehar S. Manku, Harold Bays, William G. Stirtan, Paresh N. Soni	49
9	Icosapent Ethyl, a Pure Ethyl Ester of Eicosapentaenoic Acid: Effects on Circulating Markers of Inflammation from the MARINE and ANCHOR Studies 2013 ·American Journal of Cardiovascular Drugs ·Harold Bays, Christie M. Ballantyne, Rene A. Braeckman, William G. Stirtan, Paresh N. Soni	120
10	Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients With Persistent High Triglycerides (from the ANCHOR Study) 2012 ·The American Journal of Cardiology ·Christie M. Ballantyne, Harold Bays, John J.P. Kastelein, Evan A. Stein, Jonathan L. Isaacsohn, Rene A. Braeckman, Paresh N. Soni	256
11	Abstract 15071: AMR101 Lowers Triglycerides, Atherogenic Lipoprotein, Phospholipase A2, and High-sensitivity C-reactive Protein Levels in Patients With High Triglycerides and on Background Statin Therapy (the ANCHOR Study) 2011 ·Circulation ·Christie M. Ballantyne, Harold Bays, John J.P. Kastelein, Evan A. Stein, Jonathan L. Isaacsohn, Rene A. Braeckman, Paresh N. Soni	3
12	Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients With Very High Triglyceride Levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] Trial) 2011 ·The American Journal of Cardiology ·Harold Bays, Christie M. Ballantyne, John J.P. Kastelein, Jonathan L. Isaacsohn, Rene A. Braeckman, Paresh N. Soni	275
13	PX3.102, A Novel Chinese Herb Extract, Diminishes Chronic Airway Allograft Rejection 2004 ·Transplantation ·Worakij Chalermskulrat, Isabel P. Neuringer, (unknown), W. June Brickey, Rene A. Braeckman, Scott H. Randell, Robert M. Aris	1
14	Determination of a New 5-Lipoxygenase Inhibitor, Zileuton, and its Inactive N-Dehydroxylated Metabolite in Plasma by High Performance Liquid Chromatography 1995 ·Clinical Pharmacokinetics ·G. Richard Granneman, Rene A. Braeckman, Keith Erdman	24
15	The Pharmacokinetics of Zileuton in Healthy Young and Elderly Volunteers 1995 ·Clinical Pharmacokinetics ·Rene A. Braeckman, G. Richard Granneman, Charles Locke, Joseph M. Machinist, John H. Cavanaugh, Walid M. Awni	31
16	The effect of zileuton on antipyrine and indocyanine green disposition* 1995 ·Clinical Pharmacology & Therapeutics ·John V. St. Peter, Rene A. Braeckman, G. Richard Granneman, Charles Locke, John H. Cavanaugh, Walid M. Awni	10
17	The Influence of Multiple Oral Doses of Zileuton on the Steady-State Pharmacokinetics of Sulfasalazine and its Metabolites, Sulfapyridine and N-Acetylsulfapyridine 1995 ·Clinical Pharmacokinetics ·Walid M. Awni, Rene A. Braeckman, Charles Locke, Louise M. Dubé, G. Richard Granneman	5
18	The Pharmacokinetic and Pharmacodynamic Interactions between the 5-Lipoxygenase Inhibitor Zileuton and the Cyclo-Oxygenase Inhibitor Naproxen in Human Volunteers 1995 ·Clinical Pharmacokinetics ·Walid M. Awni, Rene A. Braeckman, John H. Cavanaugh, Charles Locke, (unknown), G. Richard Granneman, Louise M. Dubé	12
19	Effect of Zileuton on Theophylline Pharmacokinetics 1995 ·Clinical Pharmacokinetics ·G. Richard Granneman, Rene A. Braeckman, Charles Locke, John H. Cavanaugh, Louise M. Dubé, Walid M. Awni	31
20	Drug distribution in dog brain studied by positron emission tomography 1988 ·Biopharmaceutics & Drug Disposition ·(unknown), Rene A. Braeckman, Dirk Van Haver, (unknown), Patrick Goethals, (unknown), (unknown), Joris Deman, Jean‐Marc Kaufman	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact